Arvinas, Inc. (Nasdaq: ARVN), announced that the U.S. Food and Drug Administration (FDA) has granted approval for VEPPANU (vepdegestrant, ARV-471) for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer.
PROTACs are bifunctional molecules that bind to the target protein and an E3 ligase, the simultaneous PROTAC binding of two proteins brings the target protein in close enough proximity for polyubiquitination by the E2 enzyme associated to the E3 ligase, which flags the target protein for degradation through the proteasome. There is more information here https://cambridgemedchemconsulting.com/proteolysis-targeting-chimeras-protacs/ including a list of PROTACS in development.




